Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

Ainda não traduzido Ainda não traduzido
Autores
Categoria Primary study
RevistaMed
Year 2024
Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%–50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.1
Epistemonikos ID: e2c15abc04f2be4d8692a412b44c60d4f1c8ace1
First added on: Feb 18, 2025